Trials / Completed
CompletedNCT04162899
A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-Blind and Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Moderate to Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- Reistone Biopharma Company Limited · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This proposed study is a randomized, double-blind, placebo-controlled, 3-arm parallel, multicenter phase II study, designed to explore the efficacy and safety of SHR0302 treatment for patients with moderate to severe atopic dermatitis. The study will be conducted over a 12-week treatment period. Two active doses of SHR0302 will be compared to placebo and improvement in atopic dermatitis will be assessed using the Investigator's Global Score (IGA)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Drug: SHR0302 | The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK-1(known as a JAK-1 inhibitor). |
Timeline
- Start date
- 2019-11-06
- Primary completion
- 2020-08-21
- Completion
- 2020-08-31
- First posted
- 2019-11-14
- Last updated
- 2023-05-09
- Results posted
- 2023-05-09
Locations
23 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04162899. Inclusion in this directory is not an endorsement.